NNZ-2591

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Phelan-McDermid Syndrome

Conditions

Phelan-McDermid Syndrome

Trial Timeline

Aug 8, 2022 → Nov 17, 2023

NCT ID

NCT05025241

About NNZ-2591

NNZ-2591 is a phase 2 stage product being developed by Neuren Pharmaceuticals for Phelan-McDermid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05025241. Target conditions include Phelan-McDermid Syndrome.

What happened to similar drugs?

0 of 1 similar drugs in Phelan-McDermid Syndrome were approved

Approved (0) Terminated (0) Active (1)

🔄NNZ-2591 + PlaceboNeuren PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05879614	Phase 2	Withdrawn	Sep 1, 2023	Jun 30, 2025	Prader-Willi Syndrome
NCT05025332	Phase 2	Completed	Oct 14, 2022	May 3, 2024	Pitt Hopkins Syndrome
NCT05025241	Phase 2	Completed	Aug 8, 2022	Nov 17, 2023	Phelan-McDermid Syndrome
NCT05011851	Phase 2	Completed	Jul 12, 2022	Jul 16, 2024	Angelman Syndrome

Competing Products

1 competing product in Phelan-McDermid Syndrome

See all competitors

Product	Company	Stage	Hype Score
NNZ-2591 + Placebo	Neuren Pharmaceuticals	Phase 3	41